Cannell Peter B & Company Boosted By $5.54 Million Its Hain Celestial Group (HAIN) Holding; Eleven Biotherapeutics (EBIO) Had 0 Bullish Analysts

September 8, 2017 - By Winifred Garcia

Cannell Peter B & Company Inc increased Hain Celestial Group Inc (HAIN) stake by 23.6% reported in 2016Q4 SEC filing. Cannell Peter B & Company Inc acquired 141,925 shares as Hain Celestial Group Inc (HAIN)’s stock rose 6.47%. The Cannell Peter B & Company Inc holds 743,335 shares with $29.01M value, up from 601,410 last quarter. Hain Celestial Group Inc now has $4.30B valuation. The stock declined 0.12% or $0.05 reaching $40.34 on the news. About 89,728 shares traded. Hain Celestial Group Inc (NASDAQ:HAIN) has declined 22.27% since September 8, 2016 and is downtrending. It has underperformed by 38.97% the S&P500.

Among 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Eleven Biotherapeutics had 4 analyst reports since August 15, 2015 according to SRatingsIntel. The company was maintained on Wednesday, March 16 by Citigroup. The rating was maintained by Leerink Swann with “Outperform” on Saturday, August 15. The firm has “Neutral” rating given on Tuesday, January 19 by Citigroup. The company was downgraded on Tuesday, January 19 by Leerink Swann. See Eleven Biotherapeutics Inc (NASDAQ:EBIO) latest ratings:

Cannell Peter B & Company Inc decreased Tjx Companies Inc (NYSE:TJX) stake by 15,475 shares to 231,117 valued at $17.36M in 2016Q4. It also reduced Lockheed Martin Corp (NYSE:LMT) stake by 1,619 shares and now owns 76,435 shares. Rayonier Inc (NYSE:RYN) was reduced too.

Investors sentiment increased to 0.96 in 2016 Q4. Its up 0.20, from 0.76 in 2016Q3. It improved, as 57 investors sold HAIN shares while 136 reduced holdings. 51 funds opened positions while 104 raised stakes. 82.90 million shares or 2.21% less from 84.77 million shares in 2016Q3 were reported. Strategic Financial Ser owns 76,893 shares or 0.58% of their US portfolio. 413,817 were reported by Principal Group. Envestnet Asset Mgmt Inc has invested 0.01% in Hain Celestial Group Inc (NASDAQ:HAIN). Putnam Fl Invest Mngmt Company reported 9,535 shares. Jnba Fin Advisors stated it has 0% of its portfolio in Hain Celestial Group Inc (NASDAQ:HAIN). Arrow Fincl Corp reported 675 shares. Synovus Financial Corp, Georgia-based fund reported 1,145 shares. Ims Capital Management holds 17,320 shares or 0.72% of its portfolio. 1,000 are held by Highlander Cap Mgmt Ltd Limited Liability Company. Blackrock Invest Mgmt Ltd reported 403,604 shares. Moreover, Mutual Of America Capital Management Ltd Limited Liability Company has 0.06% invested in Hain Celestial Group Inc (NASDAQ:HAIN) for 80,000 shares. Moreover, Walleye Trading Limited Liability Com has 0.01% invested in Hain Celestial Group Inc (NASDAQ:HAIN) for 36,113 shares. Blackrock Advsr Limited Liability owns 299,811 shares. South Dakota Invest Council owns 0.11% invested in Hain Celestial Group Inc (NASDAQ:HAIN) for 136,500 shares. Cannell Peter B Incorporated owns 743,335 shares or 1.05% of their US portfolio.

Among 30 analysts covering Hain Celestial Group (NASDAQ:HAIN), 12 have Buy rating, 2 Sell and 16 Hold. Therefore 40% are positive. Hain Celestial Group had 82 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Hain Celestial Group Inc (NASDAQ:HAIN) has “Neutral” rating given on Friday, November 18 by Bank of America. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, January 12. The rating was maintained by Maxim Group with “Hold” on Thursday, June 22. The firm earned “Neutral” rating on Friday, August 26 by Buckingham Research. The firm has “Buy” rating given on Friday, November 6 by Maxim Group. The stock of Hain Celestial Group Inc (NASDAQ:HAIN) has “Hold” rating given on Tuesday, August 29 by Susquehanna. Wedbush maintained the shares of HAIN in report on Wednesday, January 13 with “Outperform” rating. The stock of Hain Celestial Group Inc (NASDAQ:HAIN) has “Neutral” rating given on Wednesday, August 30 by Buckingham Research. Argus Research downgraded the shares of HAIN in report on Friday, February 17 to “Hold” rating. BMO Capital Markets maintained it with “Buy” rating and $48.0 target in Wednesday, August 30 report.

Investors sentiment decreased to 1.83 in Q4 2016. Its down 0.05, from 1.88 in 2016Q3. It dropped, as 6 investors sold Eleven Biotherapeutics Inc shares while 5 reduced holdings. 5 funds opened positions while 6 raised stakes. 1.14 million shares or 22.20% more from 933,766 shares in 2016Q3 were reported. Spark Inv Mngmt Limited Co holds 140,500 shares or 0.02% of its portfolio. Northern Trust owns 17,976 shares. Blackrock Institutional Na accumulated 442,085 shares or 0% of the stock. Geode Mgmt Ltd Com stated it has 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Oxford Asset Mgmt reported 179,627 shares. Natl Bank Of Mellon invested in 40,358 shares or 0% of the stock. The New York-based Citigroup has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Susquehanna Gru Ltd Liability Partnership accumulated 15,586 shares or 0% of the stock. Eagle Global has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). The United Kingdom-based Barclays Public Limited Company has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Royal Bankshares Of Canada holds 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 500 shares. Fiduciary Co invested in 10,000 shares or 0% of the stock. Blackrock Fund reported 2,365 shares stake. Price T Rowe Md holds 0% or 28,200 shares. Credit Suisse Ag reported 14,860 shares.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has market cap of $32.85 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It has a 5.99 P/E ratio. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.